1. Efficacy of gabapentin for prevention of postherpetic neuralgia: study protocol for a randomized controlled clinical trial
- Author
-
Rullan, Manuel, Bulilete, Oana, Leiva, Alfonso, Soler Mieras, Aina, Roca, Antonia, Jose Gonzalez-Bals, Maria, Lorente, Patricia, Llobera Cànaves, Joan, and PHN Grp
- Subjects
Male ,sueño ,Time Factors ,antivíricos ,Cyclohexanecarboxylic Acids ,humanos ,Herpes zoster ,Acyclovir ,Neuralgia, Postherpetic ,Medicine (miscellaneous) ,neuralgia ,Study Protocol ,0302 clinical medicine ,Clinical Protocols ,analgésicos ,ácido gamma-aminobutírico ,Surveys and Questionnaires ,valina ,Pharmacology (medical) ,030212 general & internal medicine ,Amines ,mediana edad ,gamma-Aminobutyric Acid ,Primary health care ,Pain Measurement ,Analgesics ,Dysesthesia ,resultado del tratamiento ,Valine ,ácidos ciclohexanocarboxílicos ,Middle Aged ,Allodynia ,medida del dolor ,Treatment Outcome ,Research Design ,Anesthesia ,Valacyclovir ,Hyperalgesia ,Neuropathic pain ,Postherpetic neuralgia ,Female ,medicine.symptom ,Gabapentin ,medicine.drug ,aminas ,Visual analogue scale ,Analgesic ,Antiviral Agents ,03 medical and health sciences ,factores de tiempo ,Double-Blind Method ,medicine ,Humans ,método con doble ocultación ,protocolos clínicos ,business.industry ,Prevention ,medicine.disease ,aciclovir ,Spain ,calidad de vida ,Quality of Life ,business ,Sleep ,030217 neurology & neurosurgery ,diseño de la investigación - Abstract
Background: Postherpetic neuralgia (PHN) is a chronic neuropathic pain that results from alterations of the peripheral nervous system in areas affected by the herpes zoster virus. The symptoms include pain, paresthesia, dysesthesia, hyperalgesia, and allodynia. Despite the availability of pharmacological treatments to control these symptoms, no treatments are available to control the underlying pathophysiology responsible for this disabling condition. Methods/design: Patients with herpes zoster who are at least 50 years old and have a pain score of 4 or higher on a visual analogue scale (VAS) will be recruited. The aim is to recruit 134 patients from the practices of general physicians. Participants will be randomized to receive gabapentin to a maximum of 1800 mg/day for 5 weeks or placebo. Both arms will receive 1000-mg caplets of valacyclovir three times daily for 7 days (initiated within 72 h of the onset of symptoms) and analgesics as needed. The primary outcome measure is the percentage of patients with a VAS pain score of 0 at 12 weeks from rash onset. The secondary outcomes measures are changes in quality of life (measured by the SF-12 questionnaire), sleep disturbance (measured by the Medical Outcomes Study Sleep Scale), and percentage of patients with neuropathic pain (measured by the Douleur Neuropathique in 4 Questions). Discussion: Gabapentin is an anticonvulsant type of analgesic that could prevent the onset of PHN by its antihypersensitivity action in dorsal horn neurons., This study was funded by the Ministry of Health, Carlos III Institute (grant PI12/01813). We also received support from the Health Promotion and Preventive Activities-Primary Health Care Network, sustained by the Ministry of Health, Carlos III Institute, Redes Tematicas de Investigacion Cooperativa en Salud (RETIC) award RD12/0005/0011, co-financed by the European Union European Regional Development Fund. The funders had no role in the study design, data collection, analysis, decision to publish, or preparation of the manuscript.
- Full Text
- View/download PDF